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Background: Clinical studies are a necessity for new medications and therapies. Many studies, however, struggle to
meet their recruitment numbers in time or have problems in meeting them at all. With increasing numbers of
electronic health records (EHRs) in hospitals, huge databanks emerge that could be utilized to support research. The
Innovative Medicine Initiative (IMI) funded project ‘Electronic Health Records for Clinical Research’ (EHR4CR) created
a standardized and homogenous inventory of data elements to support research by utilizing EHRs. Our aim was to
develop a Data Inventory that contains elements required for site feasibility analysis.
Methods: The Data Inventory was created in an iterative, consensus driven approach, by a group of up to 30
people consisting of pharmaceutical experts and informatics specialists. An initial list was subsequently expanded
by data elements of simplified eligibility criteria from clinical trial protocols. Each element was manually reviewed
by pharmaceutical experts and standard definitions were identified and added. To verify their availability, data
exports of the source systems at eleven university hospitals throughout Europe were conducted and evaluated.
Results: The Data Inventory consists of 75 data elements that, on the one hand are frequently used in clinical
studies, and on the other hand are available in European EHR systems. Rankings of data elements were created
from the results of the data exports. In addition a sub-list was created with 21 data elements that were separated
from the Data Inventory because of their low usage in routine documentation.
Conclusion: The data elements in the Data Inventory were identified with the knowledge of domain experts from
pharmaceutical companies. Currently, not all information that is frequently used in site feasibility is documented in
routine patient care.
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Many clinical studies have difficulties in recruiting the re-
quired number of patients within the specified time frame
and subsequent protocol amendments are costly. Between
a third and half of the studies meet their recruitment
numbers and over half take longer than planned to reach
their goal [1,2].
At the same time, clinical documentation is increasingly
carried out in electronic health record (EHR) systems
and, therefore, huge amounts of data are stored in an* Correspondence: Fleur.Fritz@uni-muenster.de
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reproduction in any medium, provided the orelectronic format. EHRs are used for routine patient care
but can also be used to support the identification of
eligible patients for clinical research [3].
If recruitment could be optimized by a better selection
of clinical research centers, and if better trial protocols
could be created through an improved and more accurate
site feasibility analysis, clinical studies could be completed
faster and be more cost-efficient. It is common practice
during feasibility analysis that pharmaceutical companies
ask physicians how many patients they treat under certain
conditions in a certain period of time. The physicians then
estimate the number of suitable patients per site. However,
how these results are compiled is non-transparent for the
study sponsor. An improvement of the site feasibilityLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to generate more reliable patient count estimates for
pharmaceutical sponsors of clinical studies and spon-
sors of investigator initiated trials (IITs) alike. If the
protocol designers know how the feasibility numbers
come about, they can redefine their criteria to improve
the protocols.
Even though EHRs are being adopted in more and more
hospitals, data is not necessarily reusable. Data can be
captured fully structured, semi-structured or in free text.
Structured data are documented during routine patient care
through the use of national value sets or terminologies, but
it is currently unclear what kind of data, besides data for
reimbursement, are available across European EHR sys-
tems. It is also unclear how much of these data are relevant
and specific enough for clinical research and which data
elements are most relevant for feasibility analyses of clinical
studies.
To tackle those issues, the IMI [4] funded project
‘Electronic Health Records for Clinical Research’ (EHR4CR)
[5] aims to support clinical trials, including site feasibility
analysis, through the re-use of EHR data. The project runs
over four years (2011 to 2014) and, being a public-private
partnership, consists of 33 partners from industry and aca-
demia. Clinical partners are located in France, Germany,
Poland, Switzerland and the United Kingdom. Scenarios
which will be addressed are ‘clinical protocol feasibility’, ‘pa-
tient identification and recruitment’, ‘clinical trial execution’
and ‘adverse event reporting’. EHR4CR is focused on the
following disease areas: oncology, inflammatory diseases,
neuroscience, diabetes, cardiovascular and respiratory dis-
eases. The project will utilize existing or specifically created
clinical data warehouses and connect those databases to
the ‘EHR4CR Platform’ in secure technical ways and com-
ply with European data protection laws.
As part of the workpackage ‘Pilots’ (WP7), we aim to
obtain an overview of the data content and frequency in
EHRs which allow electronic support for protocol feasi-
bility. Our objective is to develop an inventory of avail-
able core data elements of European EHRs for all the
disease areas of the EHR4CR project. These data ele-
ments have to be relevant for clinical research according
to clinical trial experts from the European Federation
of Pharmaceutical Industries and Associations (EFPIA).
Our motivation is to foster secondary use of EHR data
for research and our research question therefore is: What
are the common data elements in Europe relevant for siteTable 1 Data element example
Data element concept Example Consensus definition
Findings/Weight 80 kg The weight of a subject.
Example for the definition of data elements. Data element concepts consist of a da
definition and a link to the NCI Metathesaurus referencing its UMLS concept.feasibility analyses and what is currently available in
EHRs to create a valid and EFPIA accepted inventory?
Methods
Data element
The term ‘data element’ is used in several contexts with
multiple possible meanings. The ISO/IEC 11179 Standard
defines a data element in Part 1 [6] as follows:
‘A data element is produced when a representation is
associated with a data element concept. The
representation describes the form of the data,
including a value domain, datatype, representation
class (optionally), and, if necessary, a unit of measure.’
In the following, we focus on a consented definition
with a data element concept comprising two parts. The
first part is assigned to identify groups of related data
elements (data group), for example ‘Findings’, while the
second specifies the datatype in more detail (data item),
for example, ‘Weight’. Links to Unified Medical Language
System (UMLS) [7] codes are provided to identify the
underlying medical concepts. Representations, as defined
in ISO/IEC 11179, with value domains, data types and
units of measurement for each data element were not
specified for the Data Inventory, because data sources
with different languages were analyzed. Instead, examples
of typical values were provided. Table 1 shows an example
of such a data element.
Data inventory
The Data Inventory is a catalog of data elements. Every
data element consists of a data group and data item part,
which together correspond to ISO 11179’s data element
concept. Elements also contain a sequential ID, an ex-
ample for a possible data value, a definition and a link to
the UMLS code of its medical concept.
Material
The Data Inventory was created from an initial list
provided by the pharmaceutical companies with data
elements they consider most important for their stud-
ies. In addition, the inventory contains data elements
from 17 studies from acute or chronic diseases in on-
cology, neurology, diabetes, cardiovascular and inflam-
matory diseases (see Table 2). These studies were selected
from the EFPIA companies in the EHR4CR project andLink
http://ncim.nci.nih.gov/ncimbrowser/pages/concept_details.jsf?
dictionary=NCI%20MetaThesaurus&code=C0005910
ta group and data item part. The elements also contain an example, a
Table 2 Overview of the companies, the numbers and disease areas of studies used
Cardiovascular Diabetes Inflammatory Oncology Neurology
AMGEN 1
AstraZeneca 1
Bayer Health Care 2
GlaxoSmithKline 3
Johnson & Johnson 1 1
MERCK KGaA 2
Novartis Pharma AG 1 1 1
F. Hoffmann-La Roche Ltd. 1
Sanofi-Aventis 2
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lection excluded Phase I and non-interventional studies.
Additional criteria for the selection were that the studies
should have run at least at one EHR4CR data provider
site (the participating hospitals are: Assistance Publique -
Hôpitaux de Paris, Friedrich-Alexander-Universität
Erlangen-Nürnberg, Hôpitaux Universitaires de Genève,
Kings College London, Medical University of Warsaw,
Université de Rennes, University College London, University
of Dundee, University of Glasgow, University of Manchester,
Westfälische Wilhelms-Universität Münster) - preference
was given to those studies that ran at the most - and
that each EFPIA company (participating companies
are: AMGEN, AstraZeneca, Bayer Health Care, F.
Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson
& Johnson, Lilly, MERCK KGaA, Novartis Pharma
AG, Sanofi-Aventis) was represented with at least one
study. With the exception of one company, the criteria
could be met for the current version of the Data Inventory.
Data sources used for the project depend on the access
to the systems by the local partners. In total, 15 EHRs
were surveyed, because some sites used data from their
whole EHR and others data from one or more depart-
mental subsystems, for example specific systems for
breast cancer or diabetes.Figure 1 Main steps of the iterative approach to create the data inve
data elements of simplified eligibility criteria. The availability of data elemen
data exports (DE) at the sites, which afterwards get analyzed. Data element
the DI and are added to the wish list. The remaining elements form a newMethods
The process to create the Data Inventory was iterative
and consensus driven. An overview of the main steps of
our iterative approach is summarized in Figure 1. Face-
to-face meetings and telephone conferences were carried
out to achieve common understandings and agreements.
Between ten and 30 people attended the meetings and
calls, depending on their availability. As a starting
ground, pharmaceutical companies were asked to pro-
vide a list of the most commonly used data elements for
the feasibility phase, based on their own personal experi-
ence. Elements were grouped by their context to create
the data groups and afterwards the initial list was itera-
tively extended by data elements from a total of 17 stud-
ies. The data elements from the study protocols were
extracted by expert-driven, manual ‘simplification’ of
eligibility criteria [8]: feasibility and recruitment experts
from the companies removed unnecessary text phrases
or unimportant information until the core information
for ‘feasibility criteria’ remained. ‘Patient with confirmed
deep vein thrombosis’ was, for example, simplified to
‘Diagnosis/Text: deep vein thrombosis’. Data exports at the
eleven EHR4CR sites were conducted to capture the avail-
ability of each element (available yes/no) and the frequency
of documentation (measured in relative percentages) at thentory. A list of data elements (DI (previous iteration)) is extended by
ts from the extended list (Preliminary DI) then get validated through
s which are hardly used or not available at the sites get removed from
version of the Data Inventory (DI (new version)).
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that are not available in EHRs and those that are simply
not documented - both could in theory be represented as
‘0%’ - availability and frequency of a data element were
captured separately. To avoid privacy concerns and allow
for comparability between sites the relative percentage of
each element was captured instead of absolute numbers.
Relative percentages were calculated by first identifying
how many patients had an entry in the EHR for each data
element and then dividing it by the number of all pa-
tients seen in the respective time frame. These exports
were then analyzed by creating rankings and heat maps,
displaying the general availability and usage of the ele-
ments by using different colors. Microsoft Excel [9] was
used for the analysis and creation of the heat maps. The
heat maps were created using the conditional format-
ting feature.
For each iteration, consensuses on the data elements
in the Data Inventory were agreed, for example, splitting
the element ‘Child bearing status’ up into four separate
elements (‘Currently pregnant’, ‘Pregnancy number’,
‘Menopausal status’, ‘Lactation’). Other decisions were
that elements were moved to a separate list, referred to
as ‘wish list’, because they are not available or hardly
used at any of the sites.
Each of the data elements was manually reviewed by a
peer group of ten pharmaceutical and informatics
experts. The background of the pharmaceutical experts
is in feasibility assessment/management, drug safety,
data management/analytics and clinical operations. The
review was needed to determine whether the elements
were viable for the feasibility stage and whether the
meaning of the element name was clear to all peer
group members. Once a common understanding was
reached, definitions were identified and added to each
data element.
Results
In the following section, the Data Inventory in its current
version is described as well as the wish list and result from
the latest data exports.Figure 2 Examples from the data inventory. Each element in the data i
example of a possible value, the textual definition and the corresponding NData groups
The data groups define the context of the data elements.
Data groups which a data element can belong to are:
demographics, medical history, diagnosis, procedure,
findings, laboratory findings, medication, scores and
classifications, or patient characteristics.
Data Inventory
The Data Inventory in its current version is composed
of 75 elements. It consists of 5 demographics, 4 diagno-
sis, 7 findings, 41 laboratory findings, 8 medical history,
7 medication and 3 procedure data elements. The defin-
ition of each element contains a link to the correspond-
ing UMLS Concept Unique Identifiers [10] at the NCI
Metathesaurus (NCIm) [11] and a textual description. In
case the NCIm reference did not contain a textual defin-
ition, a suitable one was created by the expert group.
An overview of examples from the Data Inventory,
containing data elements from each data group, can be
seen in Figure 2. The whole Data Inventory can be found
in the additional material (Additional file 1).
Wish list
Data elements that showed through the data exports to
be not available or hardly documented were removed
from the Data Inventory and put on a separate list which
contains 21 data elements. The rarely available data ele-
ments in EHRs are listed in Table 3.
Availability of data elements
Data exports captured the availability and the usage of
the data elements. Elements which are highly available
are from the data groups demographics, diagnosis, pro-
cedures and the majority of the laboratory findings.
Rarely documented are the elements from the groups
‘scores and classifications’ and medical history, with the
exception of allergies and hypersensitivity reactions.
Medication and findings data elements are generally
available, but not in all of the systems.
The color-coded heat map (Figure 3) gives an overview
of the general availability of the data elements of thenventory contains a sequential number, the data group and item, an
CIm link.
Table 3 Data elements of the wish list
Data group Data items
Findings QTc interval, Left ventricular ejection fraction
Laboratory
findings
MAGE-A3 status
Medical
history
Trial title, Inclusion date, End of participation date,
Current method of contraception, Vaccines, HIV status,
Lactation
Patient
characteristics
Willingness to participate in clinical trials
Scores/
classifications
Date of score/Classifications, Karnofsky-score, Eastern
Cooperative Oncology Group -performance status,
TNM-classification, New York Heart Association - status,
Response Evaluation Criteria in Solid Tumors, Hoehn
and Yahr, scale, GRID-Hamilton Depression Rating Scale,
Mini-Mental State Examination, Unified Parkinson’s
Disease Rating Scale Section 1
The wish list contains data elements that are currently not, or very rarely
available, in European EHRs, but that are frequently requested in
study protocols.
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this figure were moved to the wish list after the analysis
of the heat map.
Discussion
The overall goal of this work was to identify data ele-
ments that are needed for site feasibility analysis in clin-
ical studies and are at the same time commonly
documented in European EHR systems. The heat map
was created to determine the availability across the data
provider sites. The coloring of each cell was considered
a good means to give an overview of how frequently
each element is documented and especially, highlight
those which are generally not used. Widely available data
elements are from data groups demographics, diagnosis,
procedures and laboratory findings. Under-documented
elements are those captured in the wish list which are
from the groups ‘scores and classifications’ and medical
history. We chose to use own groups instead of using
Weng et al./Luo et al.’s [12,13] semantic classes, because
our focus was not only on clinical trials, but also on
EHRs. With the data groups, we also wanted to indicate
where data could be found in EHRs. For example, proce-
dures are used in Europe for Diagnosis Related Groups
(DRG). Consequently, diagnostic and therapeutic proce-
dures would be covered by the same data group. Each
element was reviewed by feasibility and recruitment ex-
perts and contains a definition and link to the NCIm to
ensure a clear understanding and avoid confusion of the
exact meaning. Value lists, for example, diagnoses that
are frequently used for the project’s disease areas, are
not specified and out of scope of this work, therefore
they were not taken into consideration. The focus is on
availability and frequency of data elements at EHR4CRpilot sites, so only examples for values are given. The
high availability of the elements from the aforemen-
tioned data groups is most likely because they are
needed for reimbursement and quality management.
Laboratories have started structuring their data very
early, because in most cases special laboratory informa-
tion systems are connected to the main EHR. Because
the data have to be available there, laboratory findings
are also highly available. The exact reasons, however,
were not investigated. Despite the fact that a lot of
laboratory findings are available in EHRs, many labora-
tories do not yet use standard terminologies like Logical
Observation Identifiers Names and Codes (LOINC).
Classifications like the International Statistical Classifica-
tion of Diseases and Related Health Problems 10th
revision (ICD10) on the other hand, are standard in
European EHRs. That is also the reason why we used
general data elements for diagnoses and procedures, be-
cause it is generally easier to identify diagnosis and pro-
cedures data in EHRs than it is to find non standardized
data elements.
Data elements were ranked according to the availability
of the exports, so that elements of low availability could
be identified. The wish list contains those additional data
elements that are relevant for clinical research, but not
documented in a structured manner during routine care.
To enhance secondary use of data for clinical research,
EHR systems could be extended to allow a structured
documentation of these elements like the Eastern Co-
operative Oncology Group (ECOG). This would not ne-
cessarily result in more documentation work, but rather
in a different representation of the same content. Instead
of free text ‘patient is bedridden’ an ECOG score of 4
could be documented. We assume that scores like the
Mini-Mental State Examination (MMSE) and medical
history elements like ‘current method of contraception’
are primarily documented for research purposes. There is
generally no direct incentive for documentation of inten-
sive scales with many data elements, especially consider-
ing that physicians already spend equal or more time
on patient documentation than on direct patient care
[14,15]. This might indicate why those elements dropped
out of the Data Inventory and into the wish list. Likewise,
this might be the case for the medical history data
elements ‘Trial title’, ‘Inclusion date’ and ‘End of participa-
tion date’ which are also related to research. We further
assume that data elements from the data group medical
history are more frequently documented than our ex-
ports show, but most likely in free text and not as struc-
tured data. Natural language processing is not within the
scope of EHR4CR and therefore only structured data
were used. The number of data elements that can be
found in free text was not further investigated and is sub-
ject for future research.
Figure 3 Heat map of the data exports from the data inventory current version. The first two columns describe the ISO 11179 data
element concept (data group/data item). The third column shows the average usage of the data element over all sites while the following
columns (site 1 to site 9) display the frequency at the individual sites. The Data Inventory is ordered by the average usage sorted in descending
order from most available to least. The frequency ranges from 100% (dark green) to 0% (dark red). Data elements that are not available at a site
are shown as Not Available (NA) (black).
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Data Inventory, we decided to compile the list through
an iterative and consensus driven process with partners
from academia and strong participation from domain
experts of European pharmaceutical companies.
The EFPIA partners in the project are among the largest
researching pharmaceutical companies in Europe, with
many studies each year. This way both sides added theirperspectives and increased the acceptance of such a list.
The international character of the focus group and the
validation at several university hospitals makes the data
inventory meaningful beyond national borders. No ref-
erences on settings of average European hospitals were
found so whether the data exports at non-university
hospitals would have resulted in similar availability
numbers cannot be stated. An iterative approach was
Table 4 Comparison of the Data Inventory with US
cardiovascular data fields [18]
Number of data fields
matching data elements
of the Data Inventory
Exact match Data field as
value of a
data element
No match
History and physical
examination elements
8 24 5
Pharmacological therapy
data elements
0 20 0
Laboratory results elements 10 0 1
Diagnostic and therapeutic
procedures elements
2 2 26
Outcomes data elements 0 0 2
Exact matches are available in both lists; no matches means that the data field
is not represented in the Data Inventory and ‘data field as value of a data
element’ means that data fields can be matched to data elements because
they refer to similar concepts (for example, data field ‘Diabetes’ corresponds to
data elements ‘Diagnosis/Text’).
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feasible and to improve single steps of the process as we
went along. One example is, that we verified the avail-
ability of data elements in the first data export in per-
centage groups (6: 100%, 5: < 100 to 75%, 4: < 75 to
50%, 3: < 50 to 25%, 2: < 25 to 10%, 1: < 10 to > 0%, 0:
0%, N/A: not available), while in the second round,
exact relative percentages (for example, 98%) were re-
quested. Each iteration included the simplification and
identification of data elements from eligibility criteria of
study protocols. This was done by feasibility and re-
cruitment specialists from the pharmaceutical compan-
ies themselves. Analysis and processing of eligibility
criteria has been done by other groups [12,16,17], but
our aim was not to follow a specific representation or
create a new format. We wanted to extract the most im-
portant information out of those free text criteria and
display them in a simple, comprehensible way for all
stakeholders. By doing so, we were able to identify the
underlying data elements and add new ones to the Data
Inventory.
The subsequent validation exports at eleven data pro-
vider sites with varying disease specific focuses were ei-
ther done on whole EHRs or on subsystems of the
hospitals, depending on available data sources. This is
also the reason why some sites have many black cells in
Figure 3, when they used a specialized departmental
subsystem instead of the whole EHR. A bias by those
sites that used specific subsystems can therefore not be
excluded, but while general elements like ‘date of birth’
were not negatively affected, disease or gender specific
elements were influenced positively. ‘Medical history/
menopausal status’ was, for example, seldom docu-
mented in the majority of the systems, but was always
available in a breast cancer system.
Because the Data Inventory contains data elements
with clear definitions, it can be used as a reference for
important data elements when new forms are created in
EHRs. Through both lists, the Data Inventory and the
wish list, it is clearer what to expect if EHRs are to be
used for clinical research. In general, EHR systems could
be accredited for their compliance with catalogs of im-
portant data elements in the future. This could demon-
strate that the respective product is more suited to
support secondary use of health care data for clinical re-
search than non-compliant EHR systems.
The simplification of eligibility criteria was a manual
task focused on clinical trial feasibility. It is possible that
different criteria would have been identified by other
people. The Data Inventory is created as part of the
EHR4CR project and therefore, the studies were selected
to include each company and each data provider site.
This means that other studies, other disease areas and
different companies might also have resulted in differentdata elements. However, given the large number of in-
volved countries, hospitals and trial experts, this Data
Inventory represents an important consensus. Given that
EHR4CR covers six major disease areas we assume that
the Data Inventory will in general cover a large part of
clinical studies.
Related work
In the following we compare the Data Inventory against
work that relate to ours.
Weintraub et al. [18] compiled a list of 100 cardiovas-
cular ‘data fields’ that were identified from existing data
standards as being a ‘base set of terms with maximal
value’ to specified criteria. The list is intended to be used
in EHRs and facilitate secondary use, but was not vali-
dated with data exports from EHR systems.
A comparison of the data fields and the data elements
of the Data Inventory showed that because of the differ-
ent scope and definitions of data elements, both lists
cannot readily be compared. Out of the 100 data fields,
20 exactly match data elements of the Data Inventory,
while 46 are not directly captured in the Data Inventory,
but would rather be values of our data elements and 34
do not match at all. An example of a data field that
would be a value in the Data Inventory is ‘diabetes’
which we would consider a value of the data element
‘Diagnosis/text’. Table 4 shows in more detail how the
data fields correspond to the data elements.
In contrast to our work, the ‘key data elements of a
base cardiovascular vocabulary’ describe elements that
should be documented in EHRs to support the exchange
of information throughout care, while the Data Inventory
is a catalog of available data elements in EHRs that are
important for clinical research.
Häyrinen et al. [19] describe the core data elements
that were introduced in Finland for a national electronic
health record. Similar to our approach Häyrinen et al.
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item and furthermore added the terminology or code
systems that should be used, if suitable systems were ex-
istent. Häyrinen’s list contains elements that would be
implemented for the national EHR. In contrast, for our
Data Inventory we identified elements that are currently
documented in EHRs. A comparison of the ‘core data el-
ements’ and the data elements of the Data Inventory
showed several similarities: for example ‘health problems
and diagnosis’ should use ICD-10 or ICPC (International
Classification of Primary Care) codes which correlates
to ‘diagnosis/code’ of the Data Inventory. We did not
specify which classification should be used, but ICD-10
or ICPC codes would be values of this data element as
well.
Weng et al. [12] and Luo et al. [13] describe in related
publications, a semi-automatic approach that allows an-
notating free text eligibility criteria using semantic repre-
sentation. In contrast to our expert-driven simplification
approach - intended to reduce complexity with a focus on
trial feasibility - those methods aim at semi-automatically
extracting the complete information out of free text. Due
to the different approaches, there is some overlap with
our Data Inventory. Out of the 27 semantic classes from
the Weng and Luo publications, only ‘Age’ and ‘Gender’
match directly, ten classes correspond to one or more
data groups and 15 are not represented in the Data
Inventory at all. Table 5 shows how the semantic classes
correspond to the data groups.
Köpcke et al. [20] describe in their work the data com-
pleteness of five German hospital EHRs from data elements
of 15 studies re-using Luo’s semantic classes. Köpcke’s and
our work show similar tendencies for completeness and
usage. For example, age and gender are highly available and
used for both lists, although information with respect to
pregnancies is not so readily available in both. Although
[20] is focused on patient recruitment and the DataTable 5 Semantic classes from Weng [12]/Luo [13]
corresponding to the data groups
Data groups (this work) Semantic classes (Weng et al./Luo et al.)
Diagnosis Disease, Symptom and signs, Neoplasm status
Procedures Therapy or surgery, Diagnostic or lab results
Laboratory findings Diagnostic or lab results
Findings Diagnostic or lab results
Medical history Pregnancy-related activity, Addictive behavior
Scores and Classification Neoplasm status, Disease stage
Medication Pharmaceutical substance or drug
Demographics Age, Gender
Comparison between data groups of this work and semantic classes according
to Weng [12]/Luo [13]. Some of the semantic classes are listed more than once
because they correspond to more than one data group. Similarly, one data
group can correspond to one or more semantic class.Inventory on feasibility, the tendencies of availability
and usage are similar.
Lessons learned
Eligibility criteria in clinical trial protocols are usually de-
scribed using long and complicated free text sentences
which cannot readily be used for further processing.
Through a process of simplifying the criteria, the informa-
tion content can be reduced or split up in several parts
until single data elements are left, which can be repre-
sented in a formal, consistent way. When doing the simpli-
fication, we also identified a difference between required
data elements for trial feasibility and recruitment. While
the criteria for feasibility are fewer in number and more
general, data elements for recruitment have to be more
precise. From the experiences made of the simplification
task, best practice principles for simplifying eligibility cri-
teria [8] were created. They describe how eligibility criteria
should be formulated to be clearly understandable and
computer readable with little additional effort. When com-
paring the Data Inventory with billing data, in particular
DRG data [21], one can see that EHRs nowadays already
contain more data elements that can be re-used for re-
search than just diagnosis and procedure codes; laboratory
findings, for example.
Weiskopf and Weng [22] identified five common dimen-
sions of data quality reviewing 95 articles (completeness,
correctness, plausibility, concordance and currency).
Evaluating correctness, plausibility and currency is a la-
borious task which requires medical knowledge and can
therefore not be automated readily. To investigate cor-
rectness for example, patient charts would have to be
checked manually to determine if the documented data
are correct. A mapping between the data export and the
elements in the EHRs was done with knowledge of the
local project partners; the concordance however was
not evaluated in detail. However, through the data ex-
ports we did capture the availability of the data elements
(completeness) as is shown in Figure 2. During the creation
of the Data Inventory, we have seen in several instances
that data quality is a critical issue. Automatic transfer of
EHR data into an electronic data capture system for ex-
ample, can only be performed if the data quality is ‘high
enough’. The aim of the inventory, however, was not to
address these issues but to obtain an overview of what is
available and what is required.
Limitations
Certain disease areas (for example, diabetes or inflam-
matory diseases) are not yet fully covered by the Data
Inventory (see Table 2). The current version is focused
on site feasibility, so data elements for patient recruit-
ment or clinical trial execution are not considered. Our
approach was to create a global Data Inventory based on
Doods et al. Trials 2014, 15:18 Page 9 of 10
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It does not take into account varying documentation
needs of different disease areas, but should be more eas-
ily implemented in contrast to several disease-specific
data inventories.
Outlook
We expect the Data Inventory to be constantly evolving
based upon future releases of EHR systems and analyses
of more trials from different disease areas. In a review of
89 papers, Häyrinen [23] reported that use of information
systems leads to more complete and detailed documenta-
tion, and structured data entry increases completeness
and accuracy of data. Future work will focus on appropri-
ate methods and procedures to further improve EHR
data completeness and include those data elements in
routine care that are currently missing. Scope, as well as
benefits and costs need to be taken into account when
aiming to include new elements into the routine docu-
mentation. The data quality of EHRs in general, not only
the completeness, will need to be analyzed to ensure that
the data can be used for clinical studies.
Conclusion
Today, EHR systems already provide many data elements
that can be used for feasibility analysis of clinical studies.
An inventory of elements was created in a combined
effort between experts from pharmaceutical companies
and academic sites. It provides a common set of data
elements that are frequently used in clinical research and
at the same time available for re-use from current hos-
pital information systems.
Additional file
Additional file 1: Complete Data Inventory with all data elements.
The Data Inventory contains data elements for feasibility analysis that
were extracted from clinical trial protocols and that were verified to be
available in European EHR systems. The inventory contains data element
concepts (data group + data item), optional examples, the definitions
and links to NCIm.
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